Aslam Aysha, Kwo Paul Y
Stanford University School of Medicine, 430 Broadway, Pavilion C, 3rd Floor, Redwood City, CA 94063, USA.
J Clin Exp Hepatol. 2023 Jan-Feb;13(1):88-102. doi: 10.1016/j.jceh.2022.09.001. Epub 2022 Sep 20.
Consumption of alcohol in excess leads to substantial medical, economic, and societal burdens. Approximately 5.3% of all global deaths may be attributed to alcohol consumption. Moreover, the burden of alcohol associated liver disease (ALD) accounts for 5.1% of all disease and injury worldwide. Alcohol use disorder (AUD) affects men more than women globally with significant years of life loss to disability in low, middle and well-developed countries. Precise data on global estimates of alcohol related steatosis, alcohol related hepatitis, and alcohol related cirrhosis have been challenging to obtain. In the United States (US), alcohol related steatosis has been estimated at 4.3% based on NHANES data which has remained stable over 14 years. However, alcohol-related fibrotic liver disease has increased over the same period. In those with AUD, the prevalence of alcohol related hepatitis has been estimated at 10-35%. Globally, the prevalence of alcohol-associated cirrhosis has been estimated at 23.6 million individuals for compensated cirrhosis and 2.46 million for those with decompensated cirrhosis. The contribution of ALD to global mortality and disease burden of liver related deaths is substantial. In 2016 liver disease related to AUD contributed to 50% of the estimated liver disease deaths for age groups 15 years and above. Data from the US report high cost burdens associated with those admitted with alcohol-related liver complications. Finally, the recent COVID-19 pandemic has been associated with marked increase in alcohol consumption worldwide and will likely increase the burden of ALD.
过量饮酒会导致巨大的医学、经济和社会负担。全球约5.3%的死亡可能归因于饮酒。此外,酒精性肝病(ALD)的负担占全球所有疾病和损伤的5.1%。全球范围内,酒精使用障碍(AUD)对男性的影响大于女性,在低收入、中等收入和高收入国家,因残疾导致的寿命损失显著。准确获取全球酒精相关脂肪变性、酒精性肝炎和酒精性肝硬化的估计数据一直具有挑战性。在美国,根据美国国家健康与营养检查调查(NHANES)数据,酒精相关脂肪变性估计为4.3%,且在14年中一直保持稳定。然而,同期酒精相关的肝纤维化疾病有所增加。在患有酒精使用障碍的人群中,酒精性肝炎的患病率估计为10%-35%。全球范围内,酒精性肝硬化的患病率估计为代偿期肝硬化患者2360万人,失代偿期肝硬化患者246万人。酒精性肝病对全球死亡率和肝脏相关死亡的疾病负担贡献巨大。2016年,与酒精使用障碍相关的肝病导致15岁及以上年龄组估计肝病死亡人数的50%。美国的数据报告显示,与酒精相关肝脏并发症入院患者的成本负担很高。最后,最近的新冠疫情与全球酒精消费显著增加有关,可能会增加酒精性肝病的负担。